Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **bile acid conjugation process** is a biochemical pathway occurring primarily in the liver, where primary and secondary bile acids are covalently linked via an amide bond at their terminal carboxyl group with either glycine or taurine. This reaction is catalyzed by two main enzymes—bile acid-CoA synthetase (encoded by SLC27A5) and bile acid-CoA:amino acid N-acyltransferase (encoded by BAAT). Conjugation increases the amphipathic nature of bile acids, making them less toxic, more water-soluble, fully ionized at intestinal pH, and more effective as detergents for emulsifying dietary fats. This modification is essential for efficient lipid absorption, cholesterol elimination from the body, stimulation of bile flow, protection of biliary epithelium from toxicity, and regulation of cholesterol homeostasis. While critical for normal physiology and implicated in certain diseases when defective, this process itself is not considered a therapeutic target but rather an essential metabolic function involving specific enzyme targets such as BAAT or SLC27A5.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bile acid conjugation process.